Effective prophylactic therapy for cyclic vomiting syndrome in children using valproate

Area of Science:

• Pediatric Gastroenterology
• Neurology
• Pharmacology

Background:

• Cyclic Vomiting Syndrome (CVS) is a debilitating condition in children, often refractory to standard treatments.
• Previous therapies including propranolol, amitriptyline, and carbamazepine showed limited efficacy in severe pediatric CVS cases.

Purpose of the Study:

• To evaluate the efficacy and safety of valproate as a prophylactic treatment for severe cyclic vomiting syndrome in pediatric patients.
• To assess the response rate and side effects of valproate in children with CVS unresponsive to other medications.

Main Methods:

• A cohort of 13 children diagnosed with severe CVS received prophylactic valproate (10-40 mg/kg/day).
• Patients underwent diagnostic tests to exclude organic etiologies prior to treatment.
• Treatment response was evaluated based on symptom resolution, frequency, and severity of vomiting episodes.

Main Results:

• 85% of patients (11 out of 13) experienced significant improvement, with 2 showing complete resolution and 9 exhibiting marked symptom reduction.
• Two patients did not respond to valproate therapy.
• No significant side effects were observed during long-term valproate administration.

Conclusions:

• Valproate demonstrates considerable efficacy and a favorable safety profile for the prophylactic management of severe cyclic vomiting syndrome in children.
• Valproate represents a promising therapeutic option for pediatric CVS patients, particularly those with treatment-resistant symptoms.